![Sample our Bioscience journals, sign in here to start your access, Latest two full volumes FREE to you for 14 days]({"type":"image" , "src" : "/sda/5925/TOC-Subject-Sample-2021-Bioscience.jpg"})
Abstract
Angiogenesis refers to the formation of new blood vessels from existing blood vessels, a process that is believed to be a key requirement for tumour growth and metastasis. Angiogenesis inhibition represents a new approach to cancer chemotherapy and several agents and approaches are now entering late clinical development. This review summarises the key aspects of recent patent applications referring to cancer chemotherapy and cancer drug discovery that involve inhibition or reduction of angiogenesis. The review covers the main mechanism-based approaches such as MMPIs, inhibitors of the growth factor signalling pathways, integrin antagonists and urokinase inhibitors. Additional sections relating to vascular damaging agents, endogenous inhibitors and selected natural products are also included. The scope includes applications that published from October 2000 through March 2001.
- αvβ3
- αvβ5
- angiogenesis
- angiopoietin
- angiostatin
- cancer
- endostatin
- fibroblast growth factor (FGF)
- flavinoids
- Flt
- gelatinase
- growth factor inhibitors
- HGF
- integrin antagonists
- KDR
- kringle
- matrix metalloprotease (MMP)
- metastasis
- MMPI
- neovascularisation
- PDGF
- platelet factor 4
- receptor tyrosine kinases
- RGD
- stromelysin
- SU-5416
- Tek
- thrombospondin
- Tie2
- Tie-2
- TIMP
- TKI
- TMP-470
- tumour
- uPAR
- urokinase
- vascular targeting
- VEGF
- vitronectin